William Milmoe Buys 50,000 Shares of INBP
William Milmoe purchased 50,000 shares of INBP on June 24, 2026.
Key Points
- William Milmoe bought 50,000 shares of INBP on June 24, 2026, with no disclosed transaction value.
- Shares of INBP traded near $0.18 on Thursday, but no further company financials were provided.
- Other insiders, including Damon DeSantis and Eric Friedman, also bought 50,000 shares each on the same date.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
William Milmoe recently bought 50,000 shares of INBP on June 24, 2026. The transaction did not disclose a specific price or total value, but it was not part of a pre-planned trading program.
Insider Buying and Selling at Integrated BioPharma, Inc.
The recent insider buying at INBP wasn't limited to William Milmoe. On the same day, Damon DeSantis, Eric Friedman, and Robert Canarick each acquired 50,000 shares. These transactions were also not part of any pre-arranged trading plans. Earlier in the year, on April 15, 2026, William Milmoe sold 11,201,964 shares, though no specific price was noted for that transaction.
Shares of INBP were trading around $0.18 on Thursday, but further details about the company's financials or market performance aren't available at this time.
Bottom Line
The recent insider activity at INBP shows a notable amount of buying by several insiders, including William Milmoe. Insider transactions are often closely watched by investors for potential signals about the company's future. However, without more financial details or analyst ratings, it's challenging to draw broader conclusions about INBP's market position.
Get Integrated BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $INBP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.